Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Summary not available.
Pulse Biosciences (Nasdaq: PLSE) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Management is scheduled to present on Wednesday, June 10, at 10:00 am ET.
A live and recorded webcast of the fireside chat will be available on the company’s investor relations website under “Events Calendar and Presentations”.
Pulse Biosciences (Nasdaq: PLSE) reported that Co-Chairmen Robert Duggan and CEO Paul LaViolette purchased company common stock through its at-the-market equity offering program (ATM) during a designated trading window.
The Co-Chairmen acquired 675,233 shares for an aggregate purchase price of approximately $13.3 million.
Pulse Biosciences (Nasdaq: PLSE) will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on Wednesday, May 13, 2026, at 4:35 pm PT. A live and recorded webcast will be available on the company investor website’s Events Calendar and Presentations page.
Pulse Biosciences (Nasdaq: PLSE) reported Q1 2026 results and business updates on May 4, 2026. Key clinical milestones: expanded first-in-human endocardial catheter data showing 100% procedural success at 6 months (95/95), 96% at 12 months (51/53), and a 90% 12-month Kaplan-Meier freedom estimate; U.S. IDE pivotal NANOPULSE-AF enrollment started, now expected complete in early-Q4 2026. Financials: Q1 revenue $0.4M; GAAP net loss $18.6M; cash $68.3M as of March 31, 2026. Company maintains ~ $60M ATM availability and a $200M shelf registration.
Pulse Biosciences (Nasdaq: PLSE) reported late-breaking 6- and 12-month results from its first-in-human nPulse Cardiac Catheter feasibility study at Heart Rhythm 2026. Key outcomes: 6-month procedural success 95/95 (100%), 12-month success 51/53 (96%), 90% Kaplan-Meier freedom from AF/AFL/AT at one year, and 1.7% SAE rate (3/177).
Procedural metrics: left atrial dwell 18.6±13.0 min, total procedure 60.2±27.7 min, fluoroscopy 9.4±5.9 min, average PVI applications 12.3±2.6.
Pulse Biosciences (Nasdaq: PLSE) will feature its nPulse™ Cardiac Catheter and proprietary nsPFA™ nanosecond pulsed field ablation technology at the Heart Rhythm Society 2026 Annual Meeting in Chicago, April 23–26, 2026.
Highlights include a live PFA case on April 23 and a late‑breaking presentation of one‑year multicenter AF outcomes on April 25, plus posters and oral abstracts across April 24–25.
Pulse Biosciences (Nasdaq: PLSE) will host an analyst event on April 25, 2026 following its late‑breaking data presentation at Heart Rhythm Society in Chicago.
Management will review late‑breaking European feasibility data and discuss the ongoing clinical program for the nPulse Cardiac Catheter System. The hybrid event includes an online webcast with recommended log‑on by 12:45 PM CT; a replay will be posted on the company's Events Calendar.
Pulse Biosciences (NASDAQ: PLSE) appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg’s role to full-time Chief Medical Officer on April 9, 2026. Teplitsky will oversee Clinical, Regulatory, Quality, and Commercial functions as the company advances its nPulse™ Cardiac Catheter Ablation System IDE pivotal study.
The Compensation Committee granted inducement awards: a 700,000-share option and 200,000 RSUs to Teplitsky, plus 7,700 options to two new hires, at a $19.06 exercise price.
Pulse Biosciences (NASDAQ: PLSE) announced enrollment of the first patients in the NANOPULSE-AF IDE pivotal study evaluating the nPulse™ Cardiac Catheter System for recurrent, drug-resistant paroxysmal atrial fibrillation.
Early feasibility showed 96% procedural success at 12 months and 100% acute success. The system integrates with Abbott EnSite X, delivers ultra-fast nanosecond pulses (~5 seconds per application), and reported median left atrial dwell time of 21 minutes and total procedure time ~65 minutes. The pivotal study may enroll at up to 30 centers in the US and Europe.